Bryan J Neth1, Samantha N Balakrishnan2, Ivan D Carabenciov3,2, Joon H Uhm3,2, David J Daniels4, Sani H Kizilbash2, Michael W Ruff3,2. 1. Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Neth.Bryan@mayo.edu. 2. Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. 3. Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 4. Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION: Diffuse midline gliomas (DMG) with the H3 K27M-mutation are a well-described entity with most DMG harboring this mutation, with notable heterogeneity in adults. No therapy has been proven to improve survival in this tumor type. Panobinostat is a histone deacetylase inhibitor that may have therapeutic benefit. METHODS: We report our retrospective experience with use of panobinostat in adults (> 18 years) with H3 K27M-mutant DMG treated at Mayo Clinic (Rochester) from January 2016 to August 2020, with follow-up until October 2021. Survival was calculated using the Kaplan-Meier method. RESULTS: 4 patients with H3 K27M-mutant glioma were treated with panobinostat as compassionate use. Patients had a median age of 40 years (range 22-62 years) and 2 were female. Tumor location was midline for all patients, spinal cord (n = 2), brainstem (n = 1), and thalamus (n = 1). All tumors were IDH1/IDH2 wildtype. 3 patients received radiotherapy followed by adjuvant panobinostat. All patients had no other pharmacologic therapy utilized prior to or during panobinostat therapy aside from concurrent dexamethasone utilized in 3 patients. No patient experienced a grade 2 or higher (per CTCAE grade) adverse effect. The median overall survival was 42 months, median progression free survival of 19 months, 2 patients were alive at last follow up (both with spinal cord tumors and received radiation). The best response was stable disease in 2 patients and a partial response in 1 patient. CONCLUSIONS: This is the first report of clinical outcomes of panobinostat in adults with H3 K27M-mutant DMG. We showed that it is well-tolerated at the dosage schedule that we describe, with no serious adverse effects throughout the study period.
INTRODUCTION: Diffuse midline gliomas (DMG) with the H3 K27M-mutation are a well-described entity with most DMG harboring this mutation, with notable heterogeneity in adults. No therapy has been proven to improve survival in this tumor type. Panobinostat is a histone deacetylase inhibitor that may have therapeutic benefit. METHODS: We report our retrospective experience with use of panobinostat in adults (> 18 years) with H3 K27M-mutant DMG treated at Mayo Clinic (Rochester) from January 2016 to August 2020, with follow-up until October 2021. Survival was calculated using the Kaplan-Meier method. RESULTS: 4 patients with H3 K27M-mutant glioma were treated with panobinostat as compassionate use. Patients had a median age of 40 years (range 22-62 years) and 2 were female. Tumor location was midline for all patients, spinal cord (n = 2), brainstem (n = 1), and thalamus (n = 1). All tumors were IDH1/IDH2 wildtype. 3 patients received radiotherapy followed by adjuvant panobinostat. All patients had no other pharmacologic therapy utilized prior to or during panobinostat therapy aside from concurrent dexamethasone utilized in 3 patients. No patient experienced a grade 2 or higher (per CTCAE grade) adverse effect. The median overall survival was 42 months, median progression free survival of 19 months, 2 patients were alive at last follow up (both with spinal cord tumors and received radiation). The best response was stable disease in 2 patients and a partial response in 1 patient. CONCLUSIONS: This is the first report of clinical outcomes of panobinostat in adults with H3 K27M-mutant DMG. We showed that it is well-tolerated at the dosage schedule that we describe, with no serious adverse effects throughout the study period.
Authors: Daniel Haag; Norman Mack; Patricia Benites Goncalves da Silva; Britta Statz; Jessica Clark; Koji Tanabe; Tanvi Sharma; Natalie Jäger; David T W Jones; Daisuke Kawauchi; Marius Wernig; Stefan M Pfister Journal: Cancer Cell Date: 2021-02-04 Impact factor: 31.743
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Kathryn L Eschbacher; Cristiane M Ida; Derek R Johnson; Mohammed A Alvi; Sarah M Jenkins; Michael W Ruff; Panagiotis Kerezoudis; Bryan J Neth; Romela M Pasion; David J Daniels; Sani H Kizilbash; Aditya Raghunathan Journal: Am J Surg Pathol Date: 2021-08-01 Impact factor: 6.394
Authors: Sabine Mueller; Payal Jain; Winnie S Liang; Lindsay Kilburn; Cassie Kline; Nalin Gupta; Eshini Panditharatna; Suresh N Magge; Bo Zhang; Yuankun Zhu; John R Crawford; Anu Banerjee; Kellie Nazemi; Roger J Packer; Claudia K Petritsch; Nathalene Truffaux; Alison Roos; Sara Nasser; Joanna J Phillips; David Solomon; Annette Molinaro; Angela J Waanders; Sara A Byron; Michael E Berens; John Kuhn; Javad Nazarian; Michael Prados; Adam C Resnick Journal: Int J Cancer Date: 2019-04-03 Impact factor: 7.396